$33.6 M

NAVB Mkt cap, 04-Dec-2018

$231.5 K

Navidea Biopharmaceuticals Revenue Q3, 2018
Navidea Biopharmaceuticals Gross profit (Q3, 2018)193.4 K
Navidea Biopharmaceuticals Gross profit margin (Q3, 2018), %83.5%
Navidea Biopharmaceuticals Net income (Q3, 2018)-3.8 M
Navidea Biopharmaceuticals EBIT (Q3, 2018)-3.7 M
Navidea Biopharmaceuticals Cash, 30-Sep-20185.7 M
Navidea Biopharmaceuticals EV32.3 M

Navidea Biopharmaceuticals Revenue

Navidea Biopharmaceuticals revenue was $1.81 m in FY, 2017

Embed Graph

Navidea Biopharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

1.1m13.2m22.0m1.8m

Cost of goods sold

332.8k1.8m2.3m3.7k

Gross profit

797.8k11.5m19.7m1.8m

Gross profit Margin, %

71%87%90%100%

R&D expense

23.7m12.8m8.9m4.5m

General and administrative expense

15.5m17.3m13.0m11.2m

Operating expense total

39.2m30.0m21.9m15.7m

EBIT

(38.4m)(18.6m)(2.2m)(13.9m)

EBIT margin, %

(3400%)(140%)(10%)(767%)

Interest expense

2.8m6.9m14.9m169.0k

Interest income

18.8k169.0k

Pre tax profit

(42.7m)(28.8m)(14.3m)(17.8m)

Income tax expense

436.1k4.1m

Net Income

(42.7m)(27.6m)(14.3m)74.9m

Navidea Biopharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.9m5.5m7.2m1.5m2.8m

Accounts Receivable

1.2m816.5k

Inventories

2.2m652.9k1.5m

Current Assets

37.3m8.6m12.6m10.8m13.8m

PP&E

2.1m2.5m1.9m1.3m236.7k

Total Assets

40.3m11.9m15.0m12.5m20.8m

Accounts Payable

2.4m1.5m1.8m7.1m855.0k

Short-term debt

Current Liabilities

11.3m9.1m6.2m69.9m8.1m

Long-term debt

Total Debt

Total Liabilities

44.3m68.8m80.1m8.7m

Additional Paid-in Capital

313.1m323.0m326.1m326.6m331.1m

Retained Earnings

(317.3m)(353.0m)(380.5m)(394.9m)(319.9m)

Total Equity

(53.8m)12.0m

Financial Leverage

-0.3 x1.7 x

Navidea Biopharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(42.7m)(35.7m)(27.6m)(14.3m)74.9m

Accounts Receivable

(1.0m)334.1k

Inventories

(1.9m)761.0k136.0k(861.3k)1.5m

Accounts Payable

1.0m(944.8k)290.0k5.4m(6.0m)

Cash From Operating Activities

(35.6m)(29.1m)(19.1m)3.6m59.1m

Cash From Investing Activities

(1.3m)(1.5m)(27.8k)(39.2k)(1.8m)

Short-term Borrowings

(6.0m)(25.0m)(30.3m)(231.5k)

Long-term Borrowings

(6.0m)(30.3m)(231.5k)(59.8m)

Dividends Paid

Cash From Financing Activities

60.7m3.2m20.8m(9.1m)(56.0m)

Navidea Biopharmaceuticals Ratios

USDY, 2018

EV/EBIT

-8.7 x

EV/CFO

5 x

Debt/Equity

2.2 x

Debt/Assets

0.5 x

Financial Leverage

4.5 x
Report incorrect company information

Navidea Biopharmaceuticals Employee Rating

4.01 votes
Culture & Values
5.0
Work/Life Balance
5.0
Senior Management
4.0
Salary & Benefits
5.0
Career Opportunities
3.0
Source